JPMorgan Chase & Co. cut shares of Spark Therapeutics (NASDAQ:ONCE) from an overweight rating to a neutral rating in a report released on Wednesday, Marketbeat Ratings reports. The firm currently has $60.00 target price on the biotechnology company’s stock, down from their prior target price of $62.00.
A number of other research analysts have also recently commented on ONCE. Mizuho assumed coverage on Spark Therapeutics in a report on Monday, February 12th. They issued a buy rating and a $79.00 price objective on the stock. Royal Bank of Canada reiterated an outperform rating and issued a $65.00 price objective on shares of Spark Therapeutics in a report on Thursday, February 8th. Sanford C. Bernstein set a $71.00 price objective on Spark Therapeutics and gave the company a buy rating in a report on Wednesday, December 13th. Chardan Capital decreased their price objective on Spark Therapeutics from $100.00 to $60.00 and set a buy rating on the stock in a report on Tuesday, December 12th. Finally, Leerink Swann cut Spark Therapeutics from an outperform rating to a market perform rating and set a $49.00 price objective on the stock. in a report on Tuesday, December 12th. Two research analysts have rated the stock with a sell rating, five have assigned a hold rating and seventeen have given a buy rating to the company. The stock currently has a consensus rating of Buy and a consensus target price of $72.63.
Spark Therapeutics (ONCE) opened at $54.50 on Wednesday. Spark Therapeutics has a twelve month low of $41.06 and a twelve month high of $91.75. The company has a market capitalization of $2,000.00, a P/E ratio of -7.57 and a beta of 3.02.
Institutional investors have recently bought and sold shares of the company. JPMorgan Chase & Co. increased its position in shares of Spark Therapeutics by 15.0% during the third quarter. JPMorgan Chase & Co. now owns 1,848,988 shares of the biotechnology company’s stock worth $164,986,000 after acquiring an additional 241,016 shares during the period. Ameriprise Financial Inc. increased its position in shares of Spark Therapeutics by 6.0% during the third quarter. Ameriprise Financial Inc. now owns 207,360 shares of the biotechnology company’s stock worth $18,489,000 after acquiring an additional 11,785 shares during the period. BlackRock Inc. increased its position in shares of Spark Therapeutics by 11.6% during the second quarter. BlackRock Inc. now owns 2,053,734 shares of the biotechnology company’s stock worth $122,689,000 after acquiring an additional 213,520 shares during the period. Amundi Pioneer Asset Management Inc. purchased a new stake in shares of Spark Therapeutics during the third quarter worth $5,286,000. Finally, Alyeska Investment Group L.P. purchased a new stake in shares of Spark Therapeutics during the third quarter worth $13,519,000. 95.87% of the stock is currently owned by institutional investors and hedge funds.
Spark Therapeutics Company Profile
Spark Therapeutics, Inc is a gene therapy company. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its pipeline includes a product candidate targeting choroideremia (CHM), which is in a Phase I/II clinical trial and a product candidate for hemophilia A, which is in a Phase I/II clinical trial.
Receive News & Ratings for Spark Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.